St. Jude Clinical Trials
ASCIST: Donor Natural Killer Cell Infusion after Autologous CD133+ Selected Stem Cell Transplant in Treating Younger Patients with High-Risk Solid Tumors or Lymphomas
Diseases Treated:
High-risk solid tumors and lymphomas
Eligibility:
- Has a type of high-risk cancer including
- Neuroblastoma
- Solid tumors
- Lymphomas
- 21 years of age or younger
- Has not received a prior hematopoietic (blood cells from bone marrow) stem cell transplant within the previous three months
RADIANT: Donor Hematopoietic Stem Cell Transplant in Treating Young Patients with Relapsed or Refractory Solid Tumors or Lymphomas
Diseases Treated:
Relapsed or refractory solid tumors or lymphomas
Eligibility:
- Between the ages of 2 and 21 years
- Solid tumor or lymphoma as primary cancer
- Cancer that has come back or did not respond to previous chemotherapy
- No heart, kidney or liver problems
REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma
Diseases Treated:
Eligibility:
- 21 years old and younger
- Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia
- Myeloid sarcoma
- Chronic myeloid leukemia (CML)
- Juvenile myelomonocytic leukemia (JMML)
- Myelodysplastic syndrome (MDS)
- Non-Hodgkin lymphoma (NHL)
- Has a family member who is a suitable stem cell donor
Collaborative Clinical Trials
DE0605: Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
Diseases Treated:
Hepatic veno-occlusive disease
Eligibility:
- The patient must have diagnosis of hepatic VOD
- Patients must also provide voluntary written informed consent to the protocol to be eligible for the study.